Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Metabolism of BMS-986020 in Healthy Males
NCT02068053Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of bms-986020 in idiopathic pulmonary fibrosis (IPF), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at Day 11, Time of maximum observed plasma concentration at Day 11 and 10 more. Started Mar 2014; status: completed.
02
Drugs
bms-986020
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02068053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02068053.